The objective of the following review is to present the latest reports on the results of CAR-T cells directed against CD33, CD123, FLT3 and CLL-1 present on leukemic cells in the treatment of AML, the emerging challenges, as well as the prospects for the future. This evidence concerns the gene CD33 and acute myeloid leukemia.